Clinically and biologically, nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) has much more in common with germinal-centre derived B-cell NHL than classical HL. Management of NLPHL remains controversial. In a 14-year multi-centre series, 69 cases were analysed; median follow-up was 53 months (range 11-165.) B symptoms were present in only 4.3% of patients. 81.1% of patients had stage I/II disease. Treatment was with radiotherapy (53.6 %), chemotherapy (21.7%), combined modality (17.4%) and observation (7.2%.) 10.1% of patients relapsed and 2.9% of patients developed high-grade transformation to DLBCL. All relapses and transformations were salvageable. No patient died of their disease. The 5 yr relapse-free survival was 96.7%, transformation-free survival 98.4% and overall survival 100%. We conclude that NLPHL behaves as a distinct clinical entity, often presenting at early stage without risk factors. It has an excellent outcome. It may be possible to reduce intensity of therapy in NLPHL without affecting OS.
INTRODUCTION
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) comprises ~5% of all Hodgkin lymphoma. Clinically and biologically, NLPHL has more in common with germinal-centre derived Bcell non-Hodgkin lymphomas (NHLs) than classical Hodgkin Lymphoma (cHL) and clinically is characterised by male predominance, early stage disease, excellent response to treatment and good outcome. Late relapses and transformation to high-grade non-Hodgkin lymphoma (NHL) are recognised. Classical HL is characterised by a loss of the B-cell programme and expression patterns.
In contrast, the cancer cell in NLPHL, the LP cell 1 (formerly known as the "popcorn" or lymphocytic & histiocytic cell) expresses B cell markers, more in keeping with NHL, including CD20, CD79, PAX5, OCT2 and BOB1. 2 Gene expression profiling demonstrates a striking similarity to the patterns of expression seen in T-cell rich B-NHL. 3 There is a recognised risk of transformation from NLPHL to high-grade NHL, particularly diffuse large B-cell NHL (DLBCL 4 ). This risk of transformation, often long after the initial diagnosis, has been confirmed in previous studies. [5] [6] [7] Previous retrospective studies have examined the presentation of NLPHL [8] [9] [10] , however, due to its rarity and low incidence of events, there have been no published prospective randomised controlled trials in this area, outwith the context of NLPHL cases included in larger cHL trials. As a result, there is widespread variation worldwide in treatment of this condition. Such variation makes comparison of outcome data between studies challenging. On the basis of this work, however, there is a growing feeling that NLPHL, particularly limited stage (IA) disease, may be treated less intensively than cHL.
For the substantial remainder of patients, many current treatment protocols recommend management as for cHL (with chemotherapy and/or radiotherapy.) 11 It is being increasingly recognised that late toxicity with such treatments is substantial; excess risk of second cancers and cardiovascular disease continues to rise long after treatment and even 30 years after diagnosis, HL patients continue to have an elevated risk of death from all causes. 12 In spite of this, some groups argue for treatment intensification 8, 13 reporting improved responses, without improvements in overall survival.
The aim of this study is firstly to examine the clinical features at presentation of this disease, to observe whether NLPHL represents a distinct group. Secondly, the outcome of patients will be examined to assess optimal approaches to management.
MATERIALS AND METHODS

Case Ascertainment
Cases were identified through registration with the West of Scotland Cancer Network lymphoma database. The population of the area covered in the study is 2.6 million. 14 A diagnosis of NLPHL was made in 71 patients (adults and children) between 01/01/97 -31/10/10. Diagnosis was confirmed by cross-referencing with pathology reports in all cases. Most cases had pathology reviewed in the context of reference review to an expert haemato-pathologist and discussion at regional pathology team meetings. On pathological review, two patients were found to have T-cell rich DLBCL at time of initial diagnosis, and were excluded from the analysis. Thus, a total of 69 patients were included in the analysis. Eight of a total of nine re-presentations were biopsied (88%). Cases were censored as of 31/10/10. Eight patients (11.2%) were unavailable for analysis at the census date ("lost to follow up".)
As this was a retrospective non-interventional study, complete case analysis was used and these patients were censored at the date when last seen. The median follow-up time was 53 months (range
11-165 months).
Clinical Characteristics, Management And Outcomes Data was obtained using direct case-note review, using a standard form. 
Definitions
Responses were classified according to the criteria of Cheson et al. 17 Complete response (CR) was defined as complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy, or, in the case of patients in whom the PET scan was positive before therapy, a post-treatment residual mass of any size was permitted as long as it was PET negative. Partial response (PR) was defined as at least a 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses, with the additional criteria as defined above. Stable disease was defined as when a patient failed to attain the criteria needed for a CR or PR, but did not fulfil those for progressive disease. Progressive disease (PD) was defined as any new lesion or increase in SPD by> 50% of previously involved sites from the nadir.
Overall survival (OS) was measured from the date of diagnosis to date of last follow-up or death.
Relapse-free survival (RFS) is defined as time from date of diagnosis to either progression, relapse of the initial NLPHL diagnosis only, or death from any cause. Transformation-free survival (TFS) was defined as time from date of diagnosis to transformation to high-grade NHL, or death from any cause. Standard descriptive statistical analysis was performed. For crude-association analysis, data were analysed using the chi-square test. Survival analyses were calculated according using the KaplanMeier method, and presented as either survival curves or hazard curves. Analyses of OS, RFS, TFS and EFS using Cox regression were performed to assess any factors associated with these measures. Binary logistic regression was used to perform multivariate analysis of the same.
RESULTS
Patient Characteristics
The main characteristics of the 69 patients are given in In order to assess the efficacy of less-intensive treatment in early stage disease, we analysed the outcomes in the 37 (53.6%) of stage I and II patients treated with single-modality radiotherapy. In this group, outcomes were excellent with relapse-free survival of 93.9% at 5-years, transformation-free survival of 100% at 5 years and overall survival of 100% at 5 years (demonstrated in Figure 2 ).
Cox regression modelling of relapse-free and transformation free survival by age at diagnosis, clinical stage, treatment modality, presence of B symptoms, axial disease or Hasenclever score failed to give a model for predicting those patients more likely to relapse.
There were two deaths in this cohort, neither of which was related to the diagnosis of NLPHL, its transformation, relapse or treatment (the causes of death for the two patients being trauma in one case, and confirmed lung carcinoma 7.5 years after diagnosis in one of the patients who was managed by observation only.) The 5-year OS was 100% and disease specific survival was 100%.
The Kaplan-Meier plot for overall survival is given in Figure 3 .
DISCUSSION
Our study adds to the current literature in this area. Accepting the potential limitations of a retrospective cohort analysis, we suggest that the strengths of our study are its applicability to current oncology practice. As a multi-centre study with management strategies decided by individual physicians, this study is representative of practice in many settings. In contrast to recent single centre-studies, 5, 19 our cohort is restricted to cases diagnosed since 1997 which will have been managed with modern, accepted diagnostic techniques, treatments and response definitions.
We confirm that NLPHL behaves clinically as a distinct clinical entity. The majority of patients present with early stage disease, with localised peripheral lymphadenopathy. The presence of B-symptoms was unusual, and most patients had no other risk factors. All patients responded well to primary therapy, most attaining a CR.
In our study, there was a 10.1% relapse rate. Relapses and progressive disease continued to occur late in the natural history of the disease, with relapses in particular, occurring steadily to more than 10 years post first-treatment, with no sign in a plateau in the curve. This is in contrast to cHL, where much of the relapse risk is early and can be predicted in higher-risk groups of patients. Cox regression modelling of relapse-free and transformation free survival in this study failed to give a model for predicting those patients more likely to relapse. This is in itself significant, as it suggests that the natural history of this disease proceeds regardless at which stage the patient is at when diagnosed, or indeed whichever management strategy is taken. Whilst underpowered to detect equivalence, there is no evidence in our study to support the proposal that early, more intensive therapy, particularly in the form of chemotherapy will be beneficial, as has been suggested by other studies. 13 Instead, we would argue, that as relapse risk exists is unmodified by stage or first-line treatment, a strategy of minimal therapy as and when required will achieve disease control with fewer toxicities. In our study, all relapses responded fully to therapy, suggesting no advantage in earlier intensification.
Particularly striking in our cohort is the 7.2% of patients managed by observation only ("watch & wait") in whom there was no detectable difference in survival compared with the treated patients. We note that the numbers managed by observation alone are too small to demonstrate statistical significance, but our outcomes are in agreement with other studies suggesting that management by resection only may be appropriate in selected groups of limited stage patients. 20 The majority of patients were able to be treated by involved-field radiotherapy (IFRT) alone, avoiding many of the toxicities of extended field radiotherapy or chemotherapy. Previous published studies have suggested that for early stage patients, radiotherapy alone may be potentially curative. 21 The OS of 100% and EFS of 93.9% at 5 years in the stage I and II patients treated with single modality radiotherapy in our study would certainly support this approach; although we noted an ongoing risk of late relapse in this group.
As has been described in other studies [8] [9] [10] , we found an ongoing risk of evolution to high-grade NHL.
However, the risk of this was comparatively low (2.9%) and, in contrast to de novo high-grade NHL, all cases were salvageable to sustained CRs with therapy. Overall, in our study, NLPHL has an excellent outcome and there were no deaths due to lymphoma.
Some large co-operative study groups are beginning to introduce reduced-intensity treatment options for NLPHL. The EURONET paediatric protocol for NLPHL 22 is randomising between excision and observation in PET negative patients versus low intensity regimens omitting anthracycline. It is certainly interesting that the three children treated in our study received what would now be regarded as intensive therapy, with significant late toxicity (infertility) in at least one case. Current large multicentre studies on-going in the United Kingdom (e.g. NCRI RATHL) specifically exclude NLPHL. Given the CD20 positivity of this disease, recent commentators 23, 24 have suggested the addition of rituximab to chemotherapeutic regimes for NLPHL. The rationale for this is logical, the outcomes are good, and the suggestion that a putative HL stem cell may be CD20 positive supports this. 25 However, in the case of NLPHL, the natural history of the disease would support reserving this for those patients with relapsed disease, even as an alternative to chemo/radiotherapy.
Our local policy now recommends a first-line "watch and wait" strategy for those stage IA patients who are PET negative after excision biopsy, IFRT alone for stage IA and IIA patients, and six cycles of 
